According to the financial statements of the pharmaceutical company Pfizer Inc., the net profit of the American corporation by the end of 2021 increased 2.4 times to $21.979 billion. Diluted earnings per share for the year were $3.85 versus $1.63 per share a year earlier. Pfizer's revenue at the end of the reporting year doubled to $81.288 billion. Pfizer's revenue from the sale of vaccines in 2021 amounted to $13.914 billion against $2 billion in 2020. According to the results of the fourth quarter, the company received a net profit of $ 3.393 billion, which is 4 times more than in the same period in 2020. Pfizer's quarterly revenue doubled to $23.838 billion. At the same time, analysts expected an indicator of $ 24.16 billion. The company's representatives expect that in 2022, revenue from the COVID-19 vaccine developed jointly with BioNTech will amount to $32 billion. This amount also includes contracts for deliveries in the 2022-2023 fiscal year, which were signed at the end of January. Revenue from the Paxlovid anti-coronavirus drug is projected to reach $22 billion this year. Pfizer Inc. was founded in the USA in 1849 and is now one of the world leaders in the pharmaceutical industry.
